Cargando…

Exposure to nonanoic acid alters small intestinal neuroendocrine tumor phenotype

BACKGROUND: Small intestinal neuroendocrine tumors (SI-NET) are highly differentiated and genetically stable malignant tumors, yet they often present with advanced metastatic spread at the time of diagnosis. In contrast to many other types of malignant tumors, primary SI-NET are often asymptomatic a...

Descripción completa

Detalles Bibliográficos
Autores principales: Almobarak, Bilal, Amlani, Vishal, Inge, Linda, Hofving, Tobias, Muth, Andreas, Nilsson, Ola, Johansson, Martin, Arvidsson, Yvonne, Elias, Erik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035137/
https://www.ncbi.nlm.nih.gov/pubmed/36959559
http://dx.doi.org/10.1186/s12885-023-10722-8
_version_ 1784911355944370176
author Almobarak, Bilal
Amlani, Vishal
Inge, Linda
Hofving, Tobias
Muth, Andreas
Nilsson, Ola
Johansson, Martin
Arvidsson, Yvonne
Elias, Erik
author_facet Almobarak, Bilal
Amlani, Vishal
Inge, Linda
Hofving, Tobias
Muth, Andreas
Nilsson, Ola
Johansson, Martin
Arvidsson, Yvonne
Elias, Erik
author_sort Almobarak, Bilal
collection PubMed
description BACKGROUND: Small intestinal neuroendocrine tumors (SI-NET) are highly differentiated and genetically stable malignant tumors, yet they often present with advanced metastatic spread at the time of diagnosis. In contrast to many other types of malignant tumors, primary SI-NET are often asymptomatic and typically smaller in size compared to adjacent lymph node metastases. This study explores the hypothesis that stimulating the chemosensing olfactory receptor 51E1 (OR51E1) decreases SI-NET proliferation suggesting a mechanism that explains a difference in proliferative rate based on tumor location. METHODS: Clinical data was used to address difference in tumor size depending on location. A SI-NET tissue microarray was used to evaluate expression of OR51E1 and olfactory marker protein (OMP). Primary cultured tumor cells from 5 patients were utilized to determine the effect of OR51E1 agonist nonanoic acid on metabolic activity. The SI-NET cell line GOT1 was used to determine effects of nonanoic acid on the transcriptome as well as long-term effects of nonanoic acid exposure with regards to cell proliferation, serotonin secretion, alterations of the cell-cycle and morphology. RESULTS: Tumor size differed significantly based on location. OR51E1 and OMP were generally expressed in SI-NET. Primary SI-NET cells responded to nonanoic acid with a dose dependent altered metabolic activity and this was replicated in the GOT1 cell line but not in the MCF10A control cell line. Nonanoic acid treatment in GOT1 cells upregulated transcripts related to neuroendocrine differentiation and hormone secretion. Long-term nonanoic acid treatment of GOT1 cells decreased proliferation, induced senescence, and altered cell morphology. CONCLUSION: Our results raise the possibility that exposure of intraluminal metabolites could represent a mechanism determining aspects of the SI-NET tumor phenotype. However, we could not causally link the observed effects of nonanoic acid exposure to the OR51E1 receptor. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-10722-8.
format Online
Article
Text
id pubmed-10035137
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-100351372023-03-24 Exposure to nonanoic acid alters small intestinal neuroendocrine tumor phenotype Almobarak, Bilal Amlani, Vishal Inge, Linda Hofving, Tobias Muth, Andreas Nilsson, Ola Johansson, Martin Arvidsson, Yvonne Elias, Erik BMC Cancer Research BACKGROUND: Small intestinal neuroendocrine tumors (SI-NET) are highly differentiated and genetically stable malignant tumors, yet they often present with advanced metastatic spread at the time of diagnosis. In contrast to many other types of malignant tumors, primary SI-NET are often asymptomatic and typically smaller in size compared to adjacent lymph node metastases. This study explores the hypothesis that stimulating the chemosensing olfactory receptor 51E1 (OR51E1) decreases SI-NET proliferation suggesting a mechanism that explains a difference in proliferative rate based on tumor location. METHODS: Clinical data was used to address difference in tumor size depending on location. A SI-NET tissue microarray was used to evaluate expression of OR51E1 and olfactory marker protein (OMP). Primary cultured tumor cells from 5 patients were utilized to determine the effect of OR51E1 agonist nonanoic acid on metabolic activity. The SI-NET cell line GOT1 was used to determine effects of nonanoic acid on the transcriptome as well as long-term effects of nonanoic acid exposure with regards to cell proliferation, serotonin secretion, alterations of the cell-cycle and morphology. RESULTS: Tumor size differed significantly based on location. OR51E1 and OMP were generally expressed in SI-NET. Primary SI-NET cells responded to nonanoic acid with a dose dependent altered metabolic activity and this was replicated in the GOT1 cell line but not in the MCF10A control cell line. Nonanoic acid treatment in GOT1 cells upregulated transcripts related to neuroendocrine differentiation and hormone secretion. Long-term nonanoic acid treatment of GOT1 cells decreased proliferation, induced senescence, and altered cell morphology. CONCLUSION: Our results raise the possibility that exposure of intraluminal metabolites could represent a mechanism determining aspects of the SI-NET tumor phenotype. However, we could not causally link the observed effects of nonanoic acid exposure to the OR51E1 receptor. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-10722-8. BioMed Central 2023-03-23 /pmc/articles/PMC10035137/ /pubmed/36959559 http://dx.doi.org/10.1186/s12885-023-10722-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Almobarak, Bilal
Amlani, Vishal
Inge, Linda
Hofving, Tobias
Muth, Andreas
Nilsson, Ola
Johansson, Martin
Arvidsson, Yvonne
Elias, Erik
Exposure to nonanoic acid alters small intestinal neuroendocrine tumor phenotype
title Exposure to nonanoic acid alters small intestinal neuroendocrine tumor phenotype
title_full Exposure to nonanoic acid alters small intestinal neuroendocrine tumor phenotype
title_fullStr Exposure to nonanoic acid alters small intestinal neuroendocrine tumor phenotype
title_full_unstemmed Exposure to nonanoic acid alters small intestinal neuroendocrine tumor phenotype
title_short Exposure to nonanoic acid alters small intestinal neuroendocrine tumor phenotype
title_sort exposure to nonanoic acid alters small intestinal neuroendocrine tumor phenotype
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035137/
https://www.ncbi.nlm.nih.gov/pubmed/36959559
http://dx.doi.org/10.1186/s12885-023-10722-8
work_keys_str_mv AT almobarakbilal exposuretononanoicacidalterssmallintestinalneuroendocrinetumorphenotype
AT amlanivishal exposuretononanoicacidalterssmallintestinalneuroendocrinetumorphenotype
AT ingelinda exposuretononanoicacidalterssmallintestinalneuroendocrinetumorphenotype
AT hofvingtobias exposuretononanoicacidalterssmallintestinalneuroendocrinetumorphenotype
AT muthandreas exposuretononanoicacidalterssmallintestinalneuroendocrinetumorphenotype
AT nilssonola exposuretononanoicacidalterssmallintestinalneuroendocrinetumorphenotype
AT johanssonmartin exposuretononanoicacidalterssmallintestinalneuroendocrinetumorphenotype
AT arvidssonyvonne exposuretononanoicacidalterssmallintestinalneuroendocrinetumorphenotype
AT eliaserik exposuretononanoicacidalterssmallintestinalneuroendocrinetumorphenotype